# A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects

> **NCT04083833** · PHASE1 · COMPLETED · sponsor: **Wex Pharmaceuticals Inc.** · enrollment: 25 (actual)

## Conditions studied

- TQT Study

## Interventions

- **DRUG:** Tetrodotoxin
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04083833
- **Lead sponsor:** Wex Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-07
- **Primary completion:** 2018-03-24
- **Final completion:** 2018-03-24
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04083833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04083833, "A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04083833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*